Knockdown of LKB1 Sensitizes Endometrial Cancer Cells via AMPK Activation |
Rho, Seung Bae
(Division of Translational Science, Research Institute, National Cancer Center)
Byun, Hyun Jung (BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University) Kim, Boh-Ram (BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University) Lee, Chang Hoon (BK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University) |
1 | Lengyel, E., Litchfield, L. M., Mitra, A. K., Nieman, K. M., Mukherjee, A., Zhang, Y., Johnson, A., Bradaric, M., Lee, W. and Romero, I. L. (2015) Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am. J. Obstet. Gynecol. 212, 479.e1-479.e10. |
2 | Li, M., Li, X., Zhang, H. and Lu, Y. (2018) Molecular mechanisms of metformin for diabetes and cancer treatment. Front. Physiol. 9, 1039. DOI |
3 | Mallik, R. and Chowdhury, T. A. (2018) Metformin in cancer. Diabetes Res. Clin. Pract. 143, 409-419. DOI |
4 | Nangia-Makker, P., Yu, Y., Vasudevan, A., Farhana, L., Rajendra, S. G., Levi, E. and Majumdar, A. P. (2014) Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS ONE 9, e84369. DOI |
5 | Loubiere, C., Clavel, S., Gilleron, J., Harisseh, R., Fauconnier, J., BenSahra, I., Kaminski, L., Laurent, K., Herkenne, S., Lacas-Gervais, S., Ambrosetti, D., Alcor, D., Rocchi, S., Cormont, M., Michiels, J. F., Mari, B., Mazure, N. M., Scorrano, L., Lacampagne, A., Gharib, A., Tanti, J. F. and Bost, F. (2017) The energy disruptor metformin targets mitochondrial integrity via modification of calcium flux in cancer cells. Sci. Rep. 7, 5040. DOI |
6 | Ben Sahra, I., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y. and Bost, F. (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27, 3576-3586. DOI |
7 | Rho, S. B., Song, Y. J., Lim, M. C., Lee, S. H., Kim, B. R. and Park, S. Y. (2012) Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEG-FR-2. Cell. Signal. 24, 131-139. DOI |
8 | Lei, Y., Yi, Y., Liu, Y., Liu, X., Keller, E. T., Qian, C. N., Zhang, J. and Lu, Y. (2017) Metformin targets multiple signaling pathways in cancer. Chin. J. Cancer 36, 17. DOI |
9 | Algire, C., Zakikhani, M., Blouin, M. J., Shuai, J. H. and Pollak, M. (2008) Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr. Relat. Cancer 15, 833-839. DOI |
10 | Barriere, G., Tartary, M. and Rigaud, M. (2013) Metformin: a rising star to fight the epithelial mesenchymal transition in oncology. Anticancer Agents Med. Chem. 13, 333-340. DOI |
11 | Triggle, C. R. and Ding, H. (2017) Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium. Acta Physiol. 219, 138-151. DOI |
12 | Li, J., Zhong, L., Wang, F. and Zhu, H. (2017) Dissecting the role of AMP-activated protein kinase in human diseases. Acta Pharm. Sin. B 7, 249-259. DOI |
13 | Qu, C., Zhang, W., Zheng, G., Zhang, Z., Yin, J. and He, Z. (2014) Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. Mol. Cell. Biochem. 386, 63-71. DOI |
14 | Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A. and Cantley, L. C. (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. U.S.A. 101, 3329-3335. DOI |
15 | Wang, W. and Guan, K. L. (2009) AMP-activated protein kinase and cancer. Acta Physiol. 196, 55-63. DOI |
16 | Zhang, Y., Storr, S. J., Johnson, K., Green, A. R., Rakha, E. A., Ellis, I. O., Morgan, D. A. and Martin, S. G. (2014) Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy. Oncotarget 5, 12936-12949. DOI |
17 | Zhao, D., Long, X. D., Lu, T. F., Wang, T., Zhang, W. W., Liu, Y. X., Cui, X. L., Dai, H. J., Xue, F. and Xia, Q. (2015) Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma. Int. J. Cancer 136, 2556-2565. DOI |
18 | Zi, F. M., He, J. S., Li, Y., Wu, C., Yang, L., Yang, Y., Wang, L. J., He, D. H., Zhao, Y., Wu, W. J., Zheng, G. F., Han, X. Y., Huang, H., Yi, Q. and Cai, Z. (2015) Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. Cancer Lett. 356, 443-453. DOI |
19 | Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J. F. and Bost, F. (2010) Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol. Cancer Ther. 9, 1092-1099. DOI |
20 | Fogarty, S., Ross, F. A., Vara Ciruelos, D., Gray, A., Gowans, G. J. and Hardie, D. G. (2016) AMPK causes cell cycle arrest in LKB1-deficient cells via activation of CAMKK2. Mol. Cancer Res. 14, 683-695. DOI |
21 | Yuan, H. X., Xiong, Y. and Guan, K. L. (2013) Nutrient sensing, metabolism, and cell growth control. Mol. Cell 49, 379-387. DOI |
22 | Zhang, J., Xu, H., Zhou, X., Li, Y., Liu, T., Yin, X. and Zhang, B. (2017) Role of metformin in inhibiting estrogen-induced proliferation and regulating ERalpha and ERbeta expression in human endometrial cancer cells. Oncol. Lett. 14, 4949-4956. DOI |
23 | Zhu, Z., Jiang, T., Suo, H., Xu, S., Zhang, C., Ying, G. and Yan, Z. (2021) Metformin potentiates the effects of anlotinib in NSCLC via AMPK/mTOR and ROS-mediated signaling pathways. Front. Pharmacol. 12, 712181. DOI |
24 | Gotlieb, W. H., Saumet, J., Beauchamp, M. C., Gu, J., Lau, S., Pollak, M. N. and Bruchim, I. (2008) In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol. Oncol. 110, 246-250. DOI |
25 | Chen, X., Li, K. and Zhao, G. (2018) propofol inhibits hela cells by impairing autophagic flux via AMP-activated protein kinase (AMPK) activation and endoplasmic reticulum stress regulated by calcium. Med. Sci. Monit. 24, 2339-2349. DOI |
26 | Evans, J. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R. and Morris, A. D. (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330, 1304-1305. DOI |
27 | Fasih, A., Elbaz, H. A., Huttemann, M., Konski, A. A. and Zielske, S. P. (2014) Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway. Radiat. Res. 182, 50-59. DOI |
28 | Sanli, T., Rashid, A., Liu, C., Harding, S., Bristow, R. G., Cutz, J. C., Singh, G., Wright, J. and Tsakiridis, T. (2010) Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 78, 221-229. DOI |
29 | Green, A. S., Chapuis, N., Lacombe, C., Mayeux, P., Bouscary, D. and Tamburini, J. (2011) LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. Cell Cycle 10, 2115-2120. DOI |
30 | Brancher, S., Stoer, N. C., Weiderpass, E., Damhuis, R. A., Johannesen, T. B., Botteri, E. and Strand, T. E. (2021) Metformin use and lung cancer survival: a population-based study in Norway. Br. J. Cancer 124, 1018-1025. DOI |
31 | Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S. H., Bardeesy, N., Depinho, R. A., Montminy, M. and Cantley, L. C. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310, 1642-1646. DOI |
32 | Steinberg, G. R. and Kemp, B. E. (2009) AMPK in health and disease. Physiol. Rev. 89, 1025-1078. DOI |
33 | Sun, Y., Connors, K. E. and Yang, D. Q. (2007) AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner. Mol. Cell. Biochem. 306, 239-245. DOI |
34 | Towler, M. C. and Hardie, D. G. (2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ. Res. 100, 328-341. DOI |
35 | Uehara, T., Mitsuhashi, A., Tsuruoka, N. and Shozu, M. (2015) Metformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro. Oncol. Rep. 33, 744-750. DOI |
36 | Vial, G., Detaille, D. and Guigas, B. (2019) Role of mitochondria in the mechanism(s) of action of metformin. Front. Endocrinol. 10, 294. DOI |
37 | Herrero-Martin, G., Hoyer-Hansen, M., Garcia-Garcia, C., Fumarola, C., Farkas, T., Lopez-Rivas, A. and Jaattela, M. (2009) TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J. 28, 677-685. DOI |
38 | Garcia, D. and Shaw, R. J. (2017) AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. Mol. Cell 66, 789-800. DOI |
39 | Byun, H. J., Kim, B. R., Yoo, R., Park, S. Y. and Rho, S. B. (2012) sMEK1 enhances gemcitabine anti-cancer activity through inhibition of phosphorylation of Akt/mTOR. Apoptosis 17, 1095-1103. DOI |
40 | Gou, S., Cui, P., Li, X., Shi, P., Liu, T. and Wang, C. (2013) Low concentrations of metformin selectively inhibit CD133(+) cell proliferation in pancreatic cancer and have anticancer action. PLoS ONE 8, e63969. DOI |
41 | Suh, D. H., Lee, S., Park, H. S. and Park, N. H. (2020) Medroxyprogesterone reverses tolerable dose metformin-induced inhibition of invasion via matrix metallopeptidase-9 and transforming growth factor-β1 in KLE endometrial cancer cells. J. Clin. Med. 9, 3585. DOI |
42 | Xiao, X., He, Q., Lu, C., Werle, K. D., Zhao, R. X., Chen, J., Davis, B. C., Cui, R., Liang, J. and Xu, Z. X. (2012) Metformin impairs the growth of liver kinase B1-intact cervical cancer cells. Gynecol. Oncol. 127, 249-255. DOI |
43 | Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N. and Pollak, M. (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66, 10269-10273. DOI |
44 | Zhang, J. and Snyder, S. H. (1992) Nitric oxide stimulates auto-ADP-ribosylation of glyceraldehyde-3-phosphate dehydrogenase. Proc. Natl. Acad. Sci. U.S.A. 89, 9382-9385. DOI |
45 | Hardie, D. G. (2011) AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 25, 1895-1908. DOI |
46 | Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B. and Thompson, C. B. (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67, 6745-6752. DOI |
47 | Dowling, R. J., Zakikhani, M., Fantus, I. G., Pollak, M. and Sonenberg, N. (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67, 10804-10812. DOI |
48 | Liu, Y., Marks, K., Cowley, G. S., Carretero, J., Liu, Q., Nieland, T. J., Xu, C., Cohoon, T. J., Gao, P., Zhang, Y., Chen, Z., Altabef, A. B., Tchaicha, J. H., Wang, X., Choe, S., Driggers, E. M., Zhang, J., Bailey, S. T., Sharpless, N. E., Hayes, D. N., Patel, N. M., Janne, P. A., Bardeesy, N., Engelman, J. A., Manning, B. D., Shaw, R. J., Asara, J. M., Scully, R., Kimmelman, A., Byers, L. A., Gibbons, D. L., Wistuba, I. I., Heymach, J. V., Kwiatkowski, D. J., Kim, W. Y., Kung, A. L., Gray, N. S., Root, D. E., Cantley, L. C. and Wong, K. K. (2013) Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov. 3, 870-879. DOI |
49 | Whang, Y. M., Park, S. I., Trenary, I. A., Egnatchik, R. A., Fessel, J. P., Kaufman, J. M., Carbone, D. P. and Young, J. D. (2016) LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells. Oncogene 35, 856-866. DOI |
50 | Lee, B. B., Kim, Y., Kim, D., Cho, E. Y., Han, J., Kim, H. K., Shim, Y. M. and Kim, D. H. (2019) Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 downregulation in non-small cell lung cancer cells. J. Cell. Mol. Med. 23, 2872-2889. DOI |
51 | Kang, S., Dong, S. M., Kim, B. R., Park, M. S., Trink, B., Byun, H. J. and Rho, S. B. (2012) Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis 17, 989-997. DOI |
52 | Kang, G. J., Park, M. K., Byun, H. J., Kim, H. J., Kim, E. J., Yu, L., Kim, B., Shim, J. G., Lee, H. and Lee, C. H. (2020) SARNP, a participant in mRNA splicing and export, negatively regulates E-cadherin expression via interaction with pinin. J. Cell. Physiol. 235, 1543-1555. DOI |